Redox Imbalance and Mitochondrial Dysfunction Drive Gestational Diabetes Pathophysiology and Offspring Metabolic Risk

Gestational diabetes mellitus (GDM) is a complex metabolic disorder during pregnancy, posing significant risks to both mother and offspring. Traditional understanding often focuses on insulin resistance, but emerging evidence highlights the critical role of mitochondrial dysfunction and redox imbalance. These cellular impairments disrupt vital processes like oxidative phosphorylation and increase reactive oxygen species (ROS) production, leading to impaired bioenergetics and compromised maternal-fetal nutrient exchange. This review addresses the gap in comprehensively understanding how these specific cellular mechanisms contribute to GDM's progression and its long-term health consequences.

This comprehensive review synthesized current research on the intricate relationship between redox imbalance and mitochondrial dysfunction in the pathophysiology of gestational diabetes mellitus (GDM). The authors examined how these cellular impairments affect maternal health, placental function, and the metabolic programming of offspring. They analyzed findings related to impaired oxidative phosphorylation, increased reactive oxygen species (ROS) production, and the role of insufficient antioxidant protection. The review also explored alterations in mitochondrial dynamics and mitophagy as additional risk factors for placental disease, identifying placental mitochondria as potential therapeutic targets based on preclinical studies.

Mitochondrial dysfunction and redox imbalance are increasingly recognized as central to gestational diabetes mellitus (GDM) pathophysiology. The review highlights that impaired oxidative phosphorylation within the placenta, coupled with increased reactive oxygen species (ROS) production and inadequate antioxidant defenses, significantly compromises cellular bioenergetics. These disruptions directly impair maternal-fetal nutrient exchange, leading to adverse outcomes. > These changes actively promote excessive fetal growth and detrimental metabolic programming in the offspring, while simultaneously predisposing mothers to a higher risk of developing future type 2 diabetes. Furthermore, the review identifies alterations in mitochondrial dynamics and mitophagy as crucial additional risk factors contributing to placental disease. The placenta, far from being a passive organ, actively participates in metabolic signaling at the maternal-fetal interface, making its mitochondria prime therapeutic targets. Preclinical studies have demonstrated significant potential for mitochondrial antioxidants like SS-31 and MitoQ, along with uncoupling factors and biogenesis-supporting substances, in restoring mitochondrial integrity and reducing oxidative stress.